Ryosuke Watari
Overview
Explore the profile of Ryosuke Watari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watari R, Tamura N, Yoshida S, Kido Y, Matsuzaki T
J Pharm Sci
. 2024 Jun;
113(9):2871-2878.
PMID: 38885812
P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) are important transporters causing drug-drug interaction (DDI). Here, we investigated the involvement of P-gp and BCRP in the oral absorption of ensitrelvir...
2.
Kido Y, Nanchi I, Matsuzaki T, Watari R, Kiyohara H, Seki N, et al.
Drug Metab Pharmacokinet
. 2024 Apr;
56:101008.
PMID: 38663183
We aimed at predicting the drug-drug interaction (DDI) risk of P-glycoprotein (P-gp) substrates by using P-gp expressing LLC-PK1 cells and its knockout mice (KO). The area under the curve (AUC)...
3.
Nobori H, Baba K, Kuroda T, Baba K, Matsumoto K, Yoshida S, et al.
Antiviral Res
. 2024 Mar;
224:105852.
PMID: 38428748
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of coronavirus disease 2019 (COVID-19) and continues to be a major health concern worldwide. Strategies to protect individuals at...
4.
Watari R, Sawada H, Hashimoto H, Kasai Y, Oka R, Shimizu R, et al.
J Pharm Sci
. 2023 Sep;
113(3):798-805.
PMID: 37742997
Coproporphyrin-I (CP-I) has been investigated as an endogenous biomarker of organic anion transporting polypeptide (OATP) 1B. Here, we determined the CP-I concentrations in a cocktail drug-drug interaction (DDI) study of...
5.
Kuroda T, Nobori H, Fukao K, Baba K, Matsumoto K, Yoshida S, et al.
J Antimicrob Chemother
. 2023 Feb;
78(4):946-952.
PMID: 36760083
Objectives: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become established in the human population, making the need to develop safe and effective treatments critical. We have developed the small-molecule...
6.
Takubo H, Bessho K, Watari R, Shigemi R
Xenobiotica
. 2022 May;
52(4):397-404.
PMID: 35638858
Evaluation of the organic anion transporting polypeptide (OATP) 1B-mediated drug-drug interaction (DDI) potential is important for drug development. The focus of this study was coproporphyrin I (CP-I), an endogenous OATP1B...
7.
Fujiu M, Yokoo K, Sato J, Shibuya S, Komano K, Kusano H, et al.
J Med Chem
. 2021 Jun;
64(13):9496-9512.
PMID: 34143627
Coadministration of β-lactam and β-lactamase inhibitor (BLI) is one of the well-established therapeutic measures for bacterial infections caused by β-lactam-resistant Gram-negative bacteria, whereas we have only two options for orally...
8.
Nakamura A, Yasufuku K, Shimada S, Aritomi H, Furue Y, Chiba H, et al.
Neurosci Lett
. 2020 Jun;
735:135177.
PMID: 32569809
Naloxone is a μ-opioid receptor antagonist that has been used to prevent overdose-related respiratory depression and deaths by the illicit use of opioids. Naloxone can also deter the abuse potential...
9.
Watari R, Matsuda A, Ohnishi S, Hasegawa H
Drug Metab Pharmacokinet
. 2019 Feb;
34(2):126-133.
PMID: 30770183
Naldemedine tosylate, a peripherally acting μ-opioid receptor antagonist, is indicated for treatment of opioid induced constipation in both Japan and US. Naldemedine has limited ability to affect the central analgesic...
10.
Watanabe A, Watari R, Ogawa K, Shimizu R, Tanaka Y, Takai N, et al.
J Pharm Sci
. 2017 Aug;
104(3):955-961.
PMID: 28756848
In pharmacokinetic evaluation of mice, using serial sampling methods rather than a terminal blood sampling method could reduce the number of animals needed and lead to more reliable data by...